Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions

( views:, downloads: )
Author:
LIU Tao(Department of Geriatric Cardiology,Beijing Anzhen Hospital Affiliated to Capital Medical University,Beijing 100029,China;Department of Emergency,Beijing Daxing District People's Hospital,Beijing 100029,China)
XIE Ying(Department of Geriatric Cardiology,Beijing Anzhen Hospital Affiliated to Capital Medical University,Beijing 100029,China)
ZHOU Yu-jie(Department of Geriatric Cardiology,Beijing Anzhen Hospital Affiliated to Capital Medical University,Beijing 100029,China)
LI Yue-ping(Department of Geriatric Cardiology,Beijing Anzhen Hospital Affiliated to Capital Medical University,Beijing 100029,China)
MA Han-ying(Department of Geriatric Cardiology,Beijing Anzhen Hospital Affiliated to Capital Medical University,Beijing 100029,China)
GUO Yong-he(Department of Geriatric Cardiology,Beijing Anzhen Hospital Affiliated to Capital Medical University,Beijing 100029,China)
LIU Yu-yang(Department of Geriatric Cardiology,Beijing Anzhen Hospital Affiliated to Capital Medical University,Beijing 100029,China)
ZHAO Ying-xin(Department of Geriatric Cardiology,Beijing Anzhen Hospital Affiliated to Capital Medical University,Beijing 100029,China)
SHI Dong-mei(Department of Geriatric Cardiology,Beijing Anzhen Hospital Affiliated to Capital Medical University,Beijing 100029,China)
Journal Title:
CHINESE MEDICAL JOURNAL
Issue:
Volume 122, Issue 15, 2009
DOI:
10.3760/cma.j.issn.0366-6999.2009.15.003
Key Word:
tirofiban;coronary syndrome;acute;angioplasty;transluminal;percutaneous coronary

Abstract: Background For patients with moderate to high-risk acute coronary syndromes(ACS)who undergo early,invasive treatment strategies,current guidelines recommend the usage of glycoprotein(GP)lib/Illa inhibitors as an upstream treatment for a coronary care unit or as an downstream provisional treatment for selected patients who are undergoing percutaneous coronary intervention(PCI).The relative advantage of either strategy is unknown.The purpose of this study was to evaluate the effects of upstream tirofiban versus the effects of downstream tirofiban on myocardial damage and 180-day major adverse cardiovascular events(MACE)after PCI in high-risk non-ST-segment elevation ACS (NSTE-ACS)undergoing PCI.Methods From July 2006 to July 2007,160 high-risk NSTE-ACS undergoing PCI were randomized to receive upstream (within 4-6 hours before coronary angiography)tirofiban or downstream(the guidewire crossing the lesion)tirofiban,to evaluate the extent of myocardial damage after PCI by quantitatively and qualitatively analyzing the value of cardiac troponin I(cTnl)as well as MB isoenzyme of creatine kinase(CK-MB)before and after PCI.The incidences of 24-hour,3-day,7-day,30-day and 180-day MACE after PCI were followed up and the rates of bleeding complications and thrombocytopenia during tirofiban administration were recorded.Results The peak release and cumulative release of cTnl levels within 48 hours after PCI were significantly lower with upstream tirefiban than downstream tirofiban(0.45 vs 0.63 and 0.32 vs 0.43,respectively;P<0.05).Post-procedural cTnl elevation within 48 hours was significantly less frequent among patients who received the upstream tirofiban than those who received the downstream tirefiban(66.3%vs 87.5%,P<0.05).The peak and cumulative release of CK-MB levels as well as post-procedural CK-MB elevation within 48 hours after PCI were not significantly different between the two groups (16 vs 14,5 vs 3 and 26.3%vs 36.3%,respectively;P>0.05).The incidences of 24-hour,3-day,and 7-day MACE after PCI were the same between the two groups(0 vs 0,0 vs 0 and 1.25%vs 1.25%,respectively).Although the incidences of 30-day and 180-day MACE after PCI were not statisticially different between the two groups,the incidences were consistently lower with upstream tirofiban(3.75%vs 6.25%and 12.99%vs 16.67%;P>0.05).Aging(OR=1.164,P<0.001),hypertension(OR=4.165,P=0.037)and type 2 diabetes(OR=13.628,P<0.001)were independent risk factors of MACE.The timing of administrating the tirofiban(OR=2.416,P=0.153)plays an extensive role in the incidence of MACE.The incidences of major and minor bleeding complications as well as mild thrombocytopenia during the administration of tirofiban were similar between the two groups(2.50%vs 1.25%,1.25%vs 1.25%and 1.25%vs 1.25%,respectively;P>0.05).Conclusions Based on the pretreatment with aspirin and clopidogrel,upstream tirofiban was associated with attenuated minor myocardial damage and the tendency of reducing incidences of 180-day MACE after PCI among high-risk NSTE-ACS patients undergoing PCI.Aging,hypertension and type 2 diabetes were independent risk factors of MACE in high-risk NSTE-ACS patients undergoing PCI associated with tirofiban.

  • [1]Califf RM,Abdelmeguid AE,Kuntz RE,Popma JJ,Davidson C J,Cohen EA,et al.Myonecrosis after revascularization procedures.J Am Coil Cardiol 1998;31:241-251.
  • [2]Ivandic BT,Kurz K,Keck F,Staritz P,Lehrke S,Katus HA,et al.Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.Thromb Haemost 2008;100:648-654.
  • [3]Rasoul S,Ottervanger JP,de Boer M J,Dambrink JH,Suryapranata H,Hoomtje JC,et al.Routine upstream versus selective down stream use of tirofiban in non-ST elevation myocardial infarction patients scheduled for early invasive therapy;a randomized comparison.J Thromb Thrombolysis 2007;24:241-246.
  • [4]Stone GW,Bertrand ME,Moses JW,Ohman EM,Lincoff AM,Ware JH,et al.Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes:the ACUITY Timing trial.JAMA 2007;297:591-602.
  • [5]Labinaz M,Ho C,Banerjee S,Martin J,Chen S,Mensinkai S.Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneons coronary intervention.Can J Cardiol 2007;23:963-970.
  • [6]Smith SC Jr,Dove JT,Jacobs AK.ACC/AHA guidelines for percutaneous coronary intervention(revision of the 1993 PTCA guidelines)-executive summary:a report of the American College of Cardiology/American Heart Association task force on practice guidelines(Committee to revise the 1993 guidelines for percutaneous transhiminal coronary angioplasty)endorsed by the Society for Cardiac Angiography and Interventions.Circulation 2001;103:3019-3041.
  • [7]Bologuese L,Falsini G,Liistro F,Angioli P,Ducci K,Taddei T,et al.Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary inteventions:the EVEREST trial.J Am Coil Cardiol 2006;47:522-528.
  • [8]Valgimigli M,Pereoco G,Barbieri D,Ferrari E Guardigli G,Parrinello G,et al.The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty:the ADVANCE Trial.J Am Coll Cardiol 2004;44:14-19.
  • [9]Wyss CA,Roffi M.Platelet Inhibition in Percutaneous Coronary Interventions.Herz 2005;30:189-196.
  • [10]Thygesen K,Alpert JS,White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction.Universal definition of myocardial infarction.Eur Heart J 2007;28:2525-2538.
  • [11]Razakjr OA,Tan HC,Yip WL,Lira YT.Predictors of bleeding complications and thrombocytopenia with the use of abciximab during percutaneous coronary intervention.J Interv Cardiol 2005;18:33-37.
  • [12]Macdonald SE Nagree Y.Rapid risk stratification in suspected acute coronary syndrome using serial multiple cardiac biomarkers:a pilot study.Emerg Med Australas 2008;20:403-409.
  • [13]Bonz AW,Lengenfelder B,Strotmann J,Held S,Turschner O,Harre K,et al.Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel(TOPSTAR trial).J Am Coll Cardiol 2002;40:662-668.
  • [14]Li XM,Huang CX,Wang TS,Zhuang SW,Zhou H,Tian B.Comparison of coronary plaque composition among patients with acute coronary syndrome and stable coronary artery disease.Chin Med J 2008;121:534-539.
  • [15]Gravning J,Ueland T,Mφrkrid L,Endresen K,Aaberge L,Kjekshus J.Different prognostic importance of elevated troponin I after percutaneous coronary intervention in acute coronary syndrome and stable angina pectoris.Scand Cardiovasc J 2008;42:214-221.
  • [16]Okmen E,Sanli A,Uyarel H,Dayi S,Tartan Z,Cam N.Effects of glycoprotein IIb/IIIa receptor inhibition with tirofiban on minor myocardial damage in angiographically successful percutaneous coronary angioplasty.Cardiology 2004;102:18-23.
  • [17]De Servi S,Mariani M,Vandoni P,Dellavalle A,Politi A,Poletti F,et al.Use of glycoprotein IIb/IIIa inhibitors in invasively-treated patients with non-ST elevation acute coronary syndrome.J Cardiovasc Med(Hagerstown)2006;7:159-165.
  • [18]The RESTORE Investigators.Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty.Randomized efficacy study of tirofiban for outcomes and restenosis.Circulation 1997;96:1445-1453.
  • [19]EPISTENT Investigators.Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary glycoprotein IIb/IIIa blockade.Lancet 1998;352:87-92.
  • [20]Leoncini M,Toso A,Maioli M,Bellandi F,Badia T,Politi A,et al.Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach.Results of the CLOpidogrel,upstream Tirofiban,in oath Lab Downstream Abciximab(CLOTILDA)study.Am Heart J 2005;150:401.
  • [21]Bologuese L.The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.Curr Med Res Opin 2007;23:1217-1226.
  • [22]Ernst NM,Suryapranata H,Miedema K,Slingerland RJ,Ottervanger JP,Hoomtje JC,et al.Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.J Am Coil Cardiol 2004;44:1187-1193.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn